HYPNOMIDATE Solution for injection (2018)
Βιβλιογραφική αναφορά
Για την προβολή της πλήρους καταχώρησης απαιτείται συνδρομή σε ισχύ.
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή
Περιεχόμενα
Name of the medicinal product
Hypnomidate 2 mg/ml Injection.
Qualitative and quantitative composition
Each ml of Hypnomidate contains etomidate 2 mg.
Pharmaceutical form
Solution for injection.
Therapeutic indications
Hypnomidate is an intravenous induction agent of anaesthesia.
Posology and method of administration
For intravenous administration. Hypnomidate should be injected slowly by the intravenous route. The product must only be used by physicians trained in endotracheal intubation. Equipment for artificial ...
Contraindications
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Special warnings and precautions for use
Warnings: In patients with liver cirrhosis, or in those who have already received neuroleptic, opiate or sedative agents, the dose of etomidate should be reduced. Induction with Hypnomidate may be accompanied ...
Interaction with other medicinal products and other forms of interaction
The hypnotic effect of etomidate may be enhanced by neuroleptic drugs, opioids, sedatives and alcohol. Induction with etomidate may be accompanied by a slight and transient reduction in peripheral resistance ...
Fertility, pregnancy and lactation
Pregnancy In animals, no primary embryotoxic or teratogenic effects were observed with etomidate. Safety in human pregnancy has not been established. Hypnomidate should be used during pregnancy only if ...
Effects on ability to drive and use machines
Etomidate has a major influence on the ability to drive and use machines. Even though a patient may regain normal alertness 30 to 60 minutes after awakening, it is recommended that patients do not drive ...
Undesirable effects
The safety of Hypnomidate was evaluated in 812 subjects who participated in 4 open-label clinical trials of Hypnomidate used for the induction of general anaesthesia. These subjects took at least one dose ...
Overdose
Symptoms Overdosing is likely to result in prolonged anaesthesia with the possibility of respiratory depression and even arrest, in which case adequate respiratory support is mandatory. Hypotension has ...
Pharmacodynamic properties
Pharmacotherapeutic group: Other general anesthetics ATC code: N01AX07 Etomidate is a short acting intravenous hypnotic which is rapidly inactivated by enzyme metabolism so that it does not give rise to ...
Pharmacokinetic properties
Profile in Plasma After intravenous administration, the time-course of the etomidate plasma levels can be described by a three-compartment model reflecting distribution, metabolism, and elimination processes. ...
Preclinical safety data
In a reproductive fertility study, results showed no effects on fertility or general pregnancy parameters, and no signs of embryotoxicity or teratogenicity. In standard embryotoxicity and teratology studies, ...
List of excipients
Propylene glycol Water for injections 1N sodium hydroxide* 1N hydrochloric acid* * for occasional pH adjustment only
Incompatibilities
Combinations with pancuronium bromide may show a very slight opalescence; for this reason the two should not be mixed together.
Shelf life
Shelf life: 2 years.
Special precautions for storage
Do not store above 25°C.
Nature and contents of container
Colourless glass ampoule, Ph.Eur. Type I, containing 10 ml Hypnomidate, in packs of 5 and 10 ampoules. Not all pack sizes may be marketed.
Special precautions for disposal and other handling
None stated.
Marketing authorization holder
Piramal Critical Care Limited, Suite 4, Ground Floor, Heathrow Boulevard East Wing, 280 Bath Road, West Drayton, UB7 0DQ, United Kingdom, Tel: 00441670562400
Marketing authorization number(s)
PL 37071/0006
Date of first authorization / renewal of the authorization
27 October 1978/20 March 2004
Date of revision of the text
09/2018
Πηγαίο έγγραφο
Το πηγαίο έγγραφο για αυτήν την βιβλιογραφική αναφορά είναι διαθέσιμο προς μεταφόρτωση: